Interferon-γ suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPβ binding

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 8, 2007, Pages 1752-1759

  Deng, Wu Guo ^a,b   Montero, Alberto J ^a,b,d   Wu, Kenneth K ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Atherosclerosis; Cyclooxygenase 2; Inflammation; Interferon ; Plaque instability

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROTEIN C FOS; PROTEIN C JUN; PROTEIN NOXA; PROTEIN P50; TUMOR NECROSIS FACTOR ALPHA; DNA BINDING PROTEIN;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY SEQUENCE; CELL CULTURE; CYTOLOGY; ENHANCER REGION; GENE EXPRESSION REGULATION; MALE; METABOLISM; PROMOTER REGION; SENSITIVITY AND SPECIFICITY;

CCAAT-ENHANCER-BINDING PROTEINS; CELLS, CULTURED; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; ENHANCER ELEMENTS (GENETICS); FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; MALE; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; SENSITIVITY AND SPECIFICITY;

EID: 34547622603     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.144352     Document Type: Article

References (41)

1. Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol. 1995;33:179-207.
2. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci U S A. 1994;91:2046-2050.
3. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994;91:12013-12017.
4. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
5. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 1997;11:234-247.
6. Wu KK, Liou JY, Cieslik K. Transcriptional Control of COX-2 via C/EBPbeta. Arterioscler Thromb Vasc Biol. 2005;25:679-685.
7. Hershman HR. Function and regulation of prostaglandin synthase 2. Adv Exp Med Biol. 1999;469:3-8.
8. Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, Meyer-Kirchrath J, Wu KK. Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation. 2002;105:2760-2765.
9. Saunders MA, Sansores-Garcia L, Gilroy DW, Wu KK. Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem. 2001;276:18897-18904.
10. Zhu Y, Saunders MA, Yeh H, Deng WG, Wu KK. Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem. 2002;277:6923-6928.
11. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A. 1999;96:5292-5297.
12. Deng WG, Saunders MA, Gilroy DW, He XZ, Yeh H, Zhu Y, Shtivelband MI, Ruan KH, Wu KK. Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts. FASEB J. 2002;16:1286-1288.
13. Deng WG, Tang ST, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood. 2006;108:518-524.
14. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-264.
15. Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-1421.
16. Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Muller M, Decker T. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity. 2003;19:793-802.
17. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250.
18. Gough DJ, Sabapathy K, Ko EY, Arthur HA, Schreiber RD, Trapani JA, Clarke CJ, Johnstone RW. A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem. 2007;282:938-946.
19. Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM, Rose DW, Rosenfeld MG, Glass CK. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci U S A. 1997;94:1074-1079.
20. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol. 2001;167:5150-5159.
21. Ghosh AK, Yuan W, Mori Y, Chen Sj, and Varga J. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem. 2001;276:11041-11048.
22. Hertelendy F, Molnar M, Romero R. Interferon gamma antagonizes interleukin-1beta-induced cyclooxygenase-2 expression and prostaglandin E(2) production in human myometrial cells. J Soc Gynecol Investig. 2002;9:215-219.
23. Hayashi Y, Kobayashi M, Kuwata H, Atsumi G, Deguchi K, Feng Wei X, Kudo I, Hasegawa K. Interferon-gamma and interleukin 4 inhibit interleukin 1beta-induced delayed prostaglandin E(2)generation through suppression of cyclooxygenase-2 expression in human fibroblasts. Cytokine. 2000;12:603-612.
24. Tazawa R, Xu XM, Wu KK, Wang LH. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun. 1994;203:190-199.
25. Deng WG, Zhu Y, Montero A, Wu KK. Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal Biochem. 2003;323:12-18.
26. Xu XM, Tang JL, Chen X, Wang LH, Wu KK. Involvement of two Sp1 elements in basal endothelial prostaglandin H synthase-1 promoter activity. J Biol Chem. 1997;272:6943-6950.
27. Deng WG, Zhu Y, Wu KK. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem. 2003;278:4770-4777.
28. Shikama N, Lyon J, La Thangue NB. A novel cofactor for p300 that regulates the p53 response. Mol Cell. 1999;4:365-376.
29. Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 1998;14:178-183.
30. Deng WG, Zhu Y, Wu KK. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood. 2004;103:2135-2142.
31. Cieslik KA, Zhu Y, Shtivelband M, Wu KK. Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate. J Biol Chem. 2005;280:18411-18417.
32. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene. 2001;20:2438-2452.
33. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene. 2007;26:1-10.
34. Xie QW, Whisnant R, Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med. 1993;177:1779-1784.
35. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, Murphy WJ. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A. 1993;90:9730-9734.
36. Cieslik KA, Deng WG, Wu KK. Essential role of C-Rel in nitric-oxide synthase-2 transcriptional activation: time-dependent control by salicylate. Mol Pharmacol. 2006;70:2004-2014.
37. Cieslik K, Zhu Y, Wu KK. Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway. J Biol Chem. 2002;277:49304-49310.
38. Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med. 2000;191:2131-2144.
39. Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem. 2000;275:6259-6266.
40. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R, Artese L, Piattelli A, Chiarelli F, Cuccurullo F, Mezzetti A. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. 2003;107:1479-1485.
41. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.